Astrazeneca Plc Adr Stock Performance

AZN Stock  USD 77.60  1.09  1.42%   
On a scale of 0 to 100, AstraZeneca PLC holds a performance score of 18. The firm shows a Beta (market volatility) of 0.16, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AstraZeneca PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding AstraZeneca PLC is expected to be smaller as well. Please check AstraZeneca PLC's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether AstraZeneca PLC's price patterns will revert.

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC ADR are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, AstraZeneca PLC displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
1.42
Five Day Return
(0.12)
Year To Date Return
17.79
Ten Year Return
125.84
All Time Return
1.4 K
Forward Dividend Yield
0.0203
Payout Ratio
0.4344
Last Split Factor
2:1
Forward Dividend Rate
1.55
Dividend Date
2025-03-24
JavaScript chart by amCharts 3.21.151234567Dec2025Feb -5051015
JavaScript chart by amCharts 3.21.15AstraZeneca PLC ADR AstraZeneca PLC ADR Dividend Benchmark Dow Jones Industrial
1
AstraZenecas metastatic breast cancer treatment gets EU recommendation
02/28/2025
2
Onos ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyos TURALIO Dominance DelveInsight
03/04/2025
3
Amgen Challenges Novo Nordisks Ozempic And Eli Lillys Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
03/06/2025
4
IMFINZI -based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and...
03/07/2025
5
Amgen, Kyowa Kirins rocatinlimab trial for atopic dermatitis meets endpoints
03/10/2025
6
Diffblue Launches Test Review New Feature Gives Developers Versatility in Unit Testing Workflows
03/11/2025
7
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies for COVID-19
03/13/2025
Begin Period Cash Flow5.6 B
  

AstraZeneca PLC Relative Risk vs. Return Landscape

If you would invest  6,532  in AstraZeneca PLC ADR on December 15, 2024 and sell it today you would earn a total of  1,228  from holding AstraZeneca PLC ADR or generate 18.8% return on investment over 90 days. AstraZeneca PLC ADR is generating 0.2951% of daily returns assuming volatility of 1.2401% on return distribution over 90 days investment horizon. In other words, 11% of stocks are less volatile than AstraZeneca, and above 95% of all equities are expected to generate higher returns over the next 90 days.
  Expected Return   
JavaScript chart by amCharts 3.21.15CashMarketAZN 0.00.20.40.60.81.01.21.4 -0.10-0.050.000.050.100.150.200.250.30
       Risk  
Considering the 90-day investment horizon AstraZeneca PLC is expected to generate 1.37 times more return on investment than the market. However, the company is 1.37 times more volatile than its market benchmark. It trades about 0.24 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.09 per unit of risk.

AstraZeneca PLC Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for AstraZeneca PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AstraZeneca PLC ADR, and traders can use it to determine the average amount a AstraZeneca PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.238

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsAZN
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 1.24
  actual daily
11
89% of assets are more volatile

Expected Return

 0.3
  actual daily
5
95% of assets have higher returns

Risk-Adjusted Return

 0.24
  actual daily
18
82% of assets perform better
Based on monthly moving average AstraZeneca PLC is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AstraZeneca PLC by adding it to a well-diversified portfolio.

AstraZeneca PLC Fundamentals Growth

AstraZeneca Stock prices reflect investors' perceptions of the future prospects and financial health of AstraZeneca PLC, and AstraZeneca PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AstraZeneca Stock performance.
Return On Equity0.18
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Return On Asset0.0788
Profit Margin0.13 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%400%
Operating Margin0.23 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Current Valuation258.34 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Shares Outstanding3.1 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%120%
Price To Earning103.39 X
Price To Book6.19 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Price To Sales4.39 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Revenue54.07 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%500%600%
Gross Profit44.44 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%500%
EBITDA17.12 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Net Income8.69 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%
Cash And Equivalents4.52 B
Cash Per Share1.46 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%
Total Debt30.11 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%
Debt To Equity0.89 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Current Ratio0.81 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-60%-50%-40%-30%-20%-10%
Book Value Per Share26.30 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%
Cash Flow From Operations11.86 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%1,400%
Earnings Per Share2.25 X
Market Capitalization237.21 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Total Asset104.03 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%
Retained Earnings3.16 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%2,500%3,000%
Working Capital(2.04 B)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset16.01 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%500%600%
Current Liabilities14.87 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%

About AstraZeneca PLC Performance

By examining AstraZeneca PLC's fundamental ratios, stakeholders can obtain critical insights into AstraZeneca PLC's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AstraZeneca PLC is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 189.10  142.46 
Return On Tangible Assets 0.15  0.11 
Return On Capital Employed 0.13  0.24 
Return On Assets 0.07  0.10 
Return On Equity 0.17  0.34 

Things to note about AstraZeneca PLC ADR performance evaluation

Checking the ongoing alerts about AstraZeneca PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AstraZeneca PLC ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
AstraZeneca PLC ADR has 30.11 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AstraZeneca to invest in growth at high rates of return.
AstraZeneca PLC ADR has a strong financial position based on the latest SEC filings
Latest headline from finance.yahoo.com: INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies for COVID-19
Evaluating AstraZeneca PLC's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate AstraZeneca PLC's stock performance include:
  • Analyzing AstraZeneca PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AstraZeneca PLC's stock is overvalued or undervalued compared to its peers.
  • Examining AstraZeneca PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating AstraZeneca PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AstraZeneca PLC's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of AstraZeneca PLC's stock. These opinions can provide insight into AstraZeneca PLC's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating AstraZeneca PLC's stock performance is not an exact science, and many factors can impact AstraZeneca PLC's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.567
Dividend Share
3.1
Earnings Share
2.25
Revenue Per Share
2.8955
Quarterly Revenue Growth
0.238
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.